U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06903663) titled 'The Epidemiology of Patients Treated With ATZ+BEV in Real Life Setting.' on Feb. 12.
Brief Summary: Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third most frequent cause of cancer-related death.
The goal of this observational study is to learn about the long-term effects of intervention A in adult patients who take the combination of atezolizumab plus bevacizumab to treat their hepatocellular carcinoma (HCC). The main question it aims to answer is:
The clinical characteristics of patients could provide us with more data for achieving long-term response rate to ATZ plus BEV in real-life setting when co...